Development of Endogenous Protein Probes for Characterizing Surface Proteins and Cellular Interactors of Extracellular Vesicles
Extracellular vesicle (EV) surface proteins, derived from producer cells and their surrounding environment, represent a valuable source of biomarkers and participate in a plethora of biological functions, including intercellular communication. However, current methods struggle to distinguish core EV surface proteins from adsorbed corona proteins or map the EV-cell interplay. Here, a genetically encoded proximity labelling probe is presented that displays engineered ascorbate peroxidase, APEX2, on the surface of EVs via fusion to EV-sorting scaffold proteins. This enables the biotinylation of producer-cell-derived surface proteins, corona proteins, and interactors in vitro. After the enrichment by streptavidin bead pulldowns, subpopulation-specific, biotinylated surfaceome and interactome are comprehensively characterized using mass spectrometry-based proteomics. Thus, a genetic tool is introduced for the high-fidelity mapping of the surfaceome and cellular interactome of EVs in vitro. This approach offers a robust framework for dissecting EV biology and has broad applications in biomarker discovery and EV-based therapeutics.
Authors
- Metoboroghene O. Mowoe (ORCID: https://orcid.org/0000-0003-2064-7234)
- Wenqing Hou (ORCID: https://orcid.org/0000-0001-9294-9106)
- Daniel W. Hagey (ORCID: https://orcid.org/0000-0001-9246-6235)
- Koshi Imami (ORCID: https://orcid.org/0000-0002-7451-4982)
- Samir EL Andaloussi (ORCID: https://orcid.org/0000-0003-4468-9113)
- Wenyi Zheng (ORCID: https://orcid.org/0000-0003-2416-5822)
Institutions
- Karolinska University Hospital (SE)
- Karolinska Institutet (SE)
- RIKEN Center for Integrative Medical Sciences (JP)
- Chongqing Medical University (CN)
Publication Details
- Journal
- Advanced Science
- Published
- 2025-12-12
- DOI
- https://doi.org/10.1002/advs.202511414
- Primary Topic
- Extracellular vesicles in disease
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Swedish Cancer Foundation
- European Commission
- Hjärnfonden
- Novo Nordisk
- Vetenskapsrådet
- Barncancerfonden
- Novo Nordisk Fonden
- Precursory Research for Embryonic Science and Technology